Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-02-03 00:00:00 ET · period of report 2023-02-01 · accession 0001209191-23-007045 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-03 | 2023-02-01 | RXRX | Virani Shafique | Chief Business Off | A - Grant | $0.00 | +117.1K | 192.8K | +155% | $0 |
| D | 2023-02-03 | 2023-02-01 | RXRX | Virani Shafique | Chief Business Off | F - Tax | $8.55 | -2,994 | 189.8K | -2% | -$25.6K |
| D | 2023-02-03 | 2023-02-01 | RXRX | Virani Shafique | Chief Business Off | A - Grant | $0.00 | +212.5K | 212.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-02-01 | A | A | 106,253 | $0.00 | 182,003 | D | — | — | (F2) Includes 2,590 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2022. |
| 2 | Common | Class A Common Stock | 2023-02-01 | A | A | 10,837 | $0.00 | 192,840 | D | — | — | |
| 3 | Common | Class A Common Stock | 2023-02-01 | F | D | 2,994 | $8.55 | 189,846 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-02-01 | A | A | 212,507 | $0.00 | 212,507 | D | $8.55 · — to 2033-02-01 | 212,507 Class A Common Stock | (F5) The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |